We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ImmunityBio Inc | NASDAQ:IBRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.37% | 8.09 | 7.50 | 8.44 | 8.31 | 7.73 | 7.88 | 4,112,241 | 05:00:09 |
From May 2023 to May 2024
By Colin Kellaher
ImmunityBio shares rose sharply Thursday after the clinical-stage immunotherapy company said the U.S. Food and Drug Administration accepted its resubmitted application seeking approval of N-803 in certain patients with bladder cancer.
Shares of the San Diego company were recently changing hands at $1.90, up 20%.
ImmunityBio, which is seeking FDA approval of N-803 in combination with Bacillus Calmette-Guerin, or BCG, for the treatment of certain patients with BCG-unresponsive non-muscle invasive bladder cancer, said the agency set a new target action date of April 23, 2024, for the application.
The FDA in May turned away ImmunityBio's initial application, flagging deficiencies related to its inspection of the company's third-party contract-manufacturing organizations and providing recommendations regarding additional chemistry, manufacturing and controls issues and assays to be resolved.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 26, 2023 11:48 ET (15:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year ImmunityBio Chart |
1 Month ImmunityBio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
